{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?page=11&q=venetoclax", "query": { "intervention": "venetoclax", "page": 11 }, "page_size": 10 }, "pagination": { "page": 11, "page_size": 10, "total_count": 465, "total_pages": 47, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?page=12&q=venetoclax&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?page=10&q=venetoclax&page_size=10" }, "source": "remote", "last_synced_at": "2026-10-23T13:23:21.402Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT05079230", "title": "Study of Magrolimab Versus Placebo in Combination With Venetoclax and Azacitidine in Participants With Acute Myeloid Leukemia", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Acute Myeloid Leukemia" ], "interventions": [ { "name": "Magrolimab", "type": "DRUG" }, { "name": "Venetoclax", "type": "DRUG" }, { "name": "Azacitidine", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Gilead Sciences", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 378, "start_date": "2022-07-07", "completion_date": "2024-04-11", "has_results": true, "last_update_posted_date": "2025-04-04", "last_synced_at": "2026-10-23T13:23:21.402Z", "location_count": 39, "location_summary": "Little Rock, Arkansas • Duarte, California • Fresno, California + 31 more", "locations": [ { "city": "Little Rock", "state": "Arkansas" }, { "city": "Duarte", "state": "California" }, { "city": "Fresno", "state": "California" }, { "city": "Orange", "state": "California" }, { "city": "Jacksonville", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT05079230" }, { "nct_id": "NCT03069352", "title": "A Study of Venetoclax in Combination With Low Dose Cytarabine Versus Low Dose Cytarabine Alone in Treatment Naive Patients With Acute Myeloid Leukemia Who Are Ineligible for Intensive Chemotherapy", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Acute Myeloid Leukemia (AML)" ], "interventions": [ { "name": "Placebo", "type": "DRUG" }, { "name": "Venetoclax", "type": "DRUG" }, { "name": "Cytarabine", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "AbbVie", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 211, "start_date": "2017-05-29", "completion_date": "2025-08-21", "has_results": true, "last_update_posted_date": "2026-10-16", "last_synced_at": "2026-10-23T13:23:21.402Z", "location_count": 6, "location_summary": "Tampa, Florida • Louisville, Kentucky • Pittsburgh, Pennsylvania + 3 more", "locations": [ { "city": "Tampa", "state": "Florida" }, { "city": "Louisville", "state": "Kentucky" }, { "city": "Pittsburgh", "state": "Pennsylvania" }, { "city": "Houston", "state": "Texas" }, { "city": "Seattle", "state": "Washington" } ], "official_url": "https://clinicaltrials.gov/study/NCT03069352" }, { "nct_id": "NCT04227847", "title": "A Safety Study of SEA-CD70 in Patients With Myeloid Malignancies", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Myelodysplastic Syndrome", "Acute Myeloid Leukemia" ], "interventions": [ { "name": "SEA-CD70", "type": "DRUG" }, { "name": "azacitidine", "type": "DRUG" }, { "name": "Venetoclax", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Seagen, a wholly owned subsidiary of Pfizer", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 170, "start_date": "2020-08-07", "completion_date": "2028-07-03", "has_results": false, "last_update_posted_date": "2026-09-09", "last_synced_at": "2026-10-23T13:23:21.402Z", "location_count": 47, "location_summary": "Birmingham, Alabama • Duarte, California • Los Angeles, California + 18 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Birmingham", "state": "Alabama" }, { "city": "Birmingham", "state": "Alabama" }, { "city": "Duarte", "state": "California" }, { "city": "Duarte", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT04227847" }, { "nct_id": "NCT05735184", "title": "A Study to Investigate the Safety and Tolerability of Ziftomenib in Combination With Venetoclax/Azacitidine, Venetoclax, 7+3, or 7+3+Quizartinib in Patients With AML", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Acute Myeloid Leukemia", "Mixed Lineage Leukemia Gene Mutation", "Refractory AML", "AML With Mutated NPM1", "Acute Myeloid Leukemia Recurrent", "Acute Myeloid Leukemia, in Relapse", "NPM1 Mutation", "KMT2Ar", "Myeloid Sarcoma", "Nucleophosmin 1-mutated Acute Myeloid Leukemia" ], "interventions": [ { "name": "Ziftomenib", "type": "DRUG" }, { "name": "Venetoclax", "type": "DRUG" }, { "name": "Azacitidine", "type": "DRUG" }, { "name": "Daunorubicin", "type": "DRUG" }, { "name": "Cytarabine", "type": "DRUG" }, { "name": "Quizartinib", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Kura Oncology, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 420, "start_date": "2023-07-18", "completion_date": "2030-04", "has_results": false, "last_update_posted_date": "2026-03-13", "last_synced_at": "2026-10-23T13:23:21.402Z", "location_count": 44, "location_summary": "Phoenix, Arizona • La Jolla, California • Los Angeles, California + 36 more", "locations": [ { "city": "Phoenix", "state": "Arizona" }, { "city": "La Jolla", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Orange", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT05735184" }, { "nct_id": "NCT05553782", "title": "Drug Screening Using Novel IMD in Salivary and Head and Neck Cancers", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "EARLY_PHASE1" ], "conditions": [ "Salivary Gland Cancer", "Adenoid Cystic Carcinoma of the Salivary Gland", "Squamous Cell Carcinoma of Head and Neck", "Head and Neck Cancer" ], "interventions": [ { "name": "Implantable Microdevice (IMD)", "type": "COMBINATION_PRODUCT" } ], "intervention_types": [ "COMBINATION_PRODUCT" ], "sponsor": "Brigham and Women's Hospital", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 30, "start_date": "2023-11-01", "completion_date": "2029-08-01", "has_results": false, "last_update_posted_date": "2026-01-26", "last_synced_at": "2026-10-23T13:23:21.402Z", "location_count": 2, "location_summary": "Boston, Massachusetts", "locations": [ { "city": "Boston", "state": "Massachusetts" }, { "city": "Boston", "state": "Massachusetts" } ], "official_url": "https://clinicaltrials.gov/study/NCT05553782" }, { "nct_id": "NCT05529069", "title": "Phase II Study of Pirtobrutinib With Venetoclax In Relapsed-Refractory MCL (Mantle Cell Lymphoma) Patients", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Mantle Cell Lymphoma", "Non Hodgkin Lymphoma", "Hematologic Malignancy" ], "interventions": [ { "name": "Pirtobrutinib", "type": "DRUG" }, { "name": "Venetoclax", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "M.D. Anderson Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 30, "start_date": "2023-01-25", "completion_date": "2027-04-28", "has_results": false, "last_update_posted_date": "2026-05-05", "last_synced_at": "2026-10-23T13:23:21.402Z", "location_count": 1, "location_summary": "Houston, Texas", "locations": [ { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT05529069" }, { "nct_id": "NCT04855695", "title": "Avo In R/R And Previously Untreated MCL", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Mantle Cell Lymphoma", "Refractory Lymphoma" ], "interventions": [ { "name": "Acalabrutinib", "type": "DRUG" }, { "name": "Venetoclax", "type": "DRUG" }, { "name": "Obinutuzumab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Austin I Kim", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 72, "start_date": "2021-07-02", "completion_date": "2027-12-31", "has_results": false, "last_update_posted_date": "2026-01-21", "last_synced_at": "2026-10-23T13:23:21.402Z", "location_count": 3, "location_summary": "Chicago, Illinois • Boston, Massachusetts", "locations": [ { "city": "Chicago", "state": "Illinois" }, { "city": "Boston", "state": "Massachusetts" }, { "city": "Boston", "state": "Massachusetts" } ], "official_url": "https://clinicaltrials.gov/study/NCT04855695" }, { "nct_id": "NCT02419560", "title": "Optimal Dose Finding Study ABT-199 and Ibrutinib in MCL", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Lymphoma, Mantle-Cell", "Recurrent Lymphoma, Mantle-Cell" ], "interventions": [ { "name": "ABT-199 and Ibrutinib Combination", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Craig Portell, MD", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 37, "start_date": "2015-04", "completion_date": "2021-05", "has_results": false, "last_update_posted_date": "2022-05-24", "last_synced_at": "2026-10-23T13:23:21.402Z", "location_count": 4, "location_summary": "Duarte, California • Atlanta, Georgia • St Louis, Missouri + 1 more", "locations": [ { "city": "Duarte", "state": "California" }, { "city": "Atlanta", "state": "Georgia" }, { "city": "St Louis", "state": "Missouri" }, { "city": "Charlottesville", "state": "Virginia" } ], "official_url": "https://clinicaltrials.gov/study/NCT02419560" }, { "nct_id": "NCT02055820", "title": "A Study Evaluating the Safety, Efficacy and Pharmacokinetics of Venetoclax Combined With Chemotherapy in Participants With B-Cell Non-Hodgkin's Lymphoma (NHL) and DLBCL", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Lymphoma, Non-Hodgkin" ], "interventions": [ { "name": "Venetoclax", "type": "DRUG" }, { "name": "Cyclophosphamide", "type": "DRUG" }, { "name": "Obinutuzumab", "type": "DRUG" }, { "name": "Rituximab", "type": "DRUG" }, { "name": "Doxorubicin", "type": "DRUG" }, { "name": "Vincristine", "type": "DRUG" }, { "name": "Prednisone", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Hoffmann-La Roche", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 267, "start_date": "2013-11-17", "completion_date": "2019-06-28", "has_results": true, "last_update_posted_date": "2020-06-11", "last_synced_at": "2026-10-23T13:23:21.402Z", "location_count": 9, "location_summary": "Fullerton, California • Los Angeles, California • Santa Maria, California + 6 more", "locations": [ { "city": "Fullerton", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Santa Maria", "state": "California" }, { "city": "St Louis", "state": "Missouri" }, { "city": "Hackensack", "state": "New Jersey" } ], "official_url": "https://clinicaltrials.gov/study/NCT02055820" }, { "nct_id": "NCT05268003", "title": "A Phase II Study of the Combination of Ponatinib With Mini-hyper CVD Chemotherapy and Venetoclax in Patients With Relapsed or Refractory T-cell Acute Lymphoblastic Leukemia", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Acute Lymphoblastic Leukemia", "Leukemia" ], "interventions": [ { "name": "Ponatinib", "type": "DRUG" }, { "name": "Venetoclax", "type": "DRUG" }, { "name": "Mini-hyper CVD", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "M.D. Anderson Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "12 Years", "maximum_age": null, "sex": "ALL", "summary": "12 Years and older" }, "enrollment_count": 4, "start_date": "2022-06-07", "completion_date": "2026-04-21", "has_results": false, "last_update_posted_date": "2026-04-27", "last_synced_at": "2026-10-23T13:23:21.402Z", "location_count": 1, "location_summary": "Houston, Texas", "locations": [ { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT05268003" } ] }